Good news | Jiangxi Starry Gadobenate dimeglumine API approved for marketing

2024-02-22

On 20th February, Jiangxi Starry received the marketing approval notice of Gadobenate dimeglumine API from NMPA and obtained a drug registration certificate (Registration No.: YBY60202024).

The marketing approval of Gadobenate dimeglumine API,as an important step for Starry Pharmaceutical to pursue the strategy of whole industry chain for contrast agent ,can be seen as another achievement during the transformation from intermediate production to API production in Jiangxi Starry. Starry is firmly committed to this strategy and persisting in building up its core competitiveness of API and FDF Integration. Aimed to provide more medicines of high quality to domestic customers, Starry is working hard to further deepening the technological R&D and product innovation in the field of medical imaging.

About Gadobenate dimeglumine

Gadobenate dimeglumine is a type of magnetic resonance imaging (MRI) contrast agent,mainly used in the diagnosis of the diseases of liver and central nervous system. In terms of liver, it is indicated for the detection of focal liver injury in patients known or suspected with primary liver cancer (e.g., hepatocellular carcinoma) or focal hepatic lesion. In terms of CNS, it applies to MRI-enhanced examinations for brains and spines and can improve the detection efficiency. Compared to traditional unenhanced MRI, it can provide more diagnostic information.

Last page

Bureau of Statistics Shanghai Jinshan District Visited Shanghai Starry

Good news|Shanghai Starry loversol lnjection approved for marketing

Last page

Bureau of Statistics Shanghai Jinshan District Visited Shanghai Starry

Good news|Shanghai Starry loversol lnjection approved for marketing

Related news

2024-02-29

Bureau of Statistics Shanghai Jinshan District Visited Shanghai Starry

2024-02-22

Good news | Jiangxi Starry Gadobenate dimeglumine API approved for marketing

2023-10-31